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1 Abstract  
1.1 Purpose 
It is challenging to provide equal access to advanced diagnostics in the sub-arctic region of 
Norway. The goal of providing a high quality to Positron Emission Tomography/Computer 
Tomography centre (PET/CT) is challenging due to vast distances and weather condition. 
This study is a follow-up study on a previous analysis done by Norum et al. to examine the 
availability of the PET/CT service in the University Hospital in Northern Norway (UNN), 
situated in the city of Tromsø. 
1.2 Method 
In 2016, the patient data from all PET/CT examinations in 2014 and 2015 was retrospectively 
analysed. The data was divided in subgroups based on gender, home address, county, age and 
diagnosis. Descriptive statistics was performed, and subgroups were compared using 
Pearson’s Chi-Square test to detect and quantify any inequality in access to PET/CT 
examination. 
1.3 Results 
In 2014 and 2015 a total of 907 PET/CT scans were performed in 825 patients at the PET 
Imaging Centre in UNN, Tromsø, giving an average of 1,1 PET/CT examinations per patient. 
In 2015 there was an average of 1069 PET/CT scans per million in Northern Norway. Lung 
cancer (36,4%), lymphoma (18,0%), head and neck cancer (10,0%), and malignant melanoma 
(6,7%) were the most frequent diagnostic groups. The northernmost county, Finnmark, had 
more PET/CT scans than both Troms and Nordland (P=0,012) on average, but the distribution 
between counties varied with the diagnostic group. Nordland had more PET/CT scans in 
malignant melanoma patients than both Troms and Finnmark. The mean travelling distance to 
the PET centre were 406 km with range from 4,8 km to 939 km. 
1.4 Conclusion  
The difference in availability to PET/CT examination between counties in Northern Norway 
has decreased since 2010-2013, but there is still a difference present. Finnmark has on average 
more PET/CT examinations per head of population, while Nordland has more scans in 
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malignant melanoma patients. The difference in cancer incidence cannot explain this difference 
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2 Introduction  
 
2.1 Medical imaging 
Radiology as a medical field began with Wilhelm Röntgen’s discovery of X-rays in 1895 while 
working with his cathode ray tube. For this he was awarded the Nobel Prize in Physics in 1901 
(1). People soon began to realise the potential medical uses for the technology, and the first 
clinical X-ray image was done in 1896 (2). The further development of radiographic films and 
screens made x-ray imaging more popular during the 1920s (3). 
Today, there are several modalities in medical imaging, each with their own advantages and 
disadvantages. The most common in use are 
- X-ray (Projectional radiograph)  
- X-ray Computed Tomography (CT)  
- Magnetic Resonance Imaging (MRI)  
- Ultrasound devices. 
All these modalities have in common that they can examine the patient’s anatomy and physical 
properties non-invasively (3). 
 
2.2 Nuclear medicine 
 
Nuclear medicine uses radioactive isotopes to do both medical imaging and therapeutics. This 
differs from radiological modalities in that nuclear imaging depend on molecular biology and 
physiological processes to generate pictures, where radiological modalities depend on physical 
properties of the chemical structures in the body to generate pictures, whether this is electron 
density (x-ray), echogenic properties (ultrasound) or proton density (MRI) (4).  
Radioactive isotopes chemically bonded to a biologically active molecule 
(radiopharmaceutical) can in theory image all biological pathways in the body, depending on 
the radiopharmaceutical in use.  
 
 
Page 6 of 25 
 
The most common modalities in nuclear imaging are (5): 
- Scintigraphy 
- Single photon emission computed tomography (SPECT) 
- Positron emission tomography (PET) 
These modalities are often combined with CT, or recently MRI, to make a hybrid scanner. This 
produces both good contrast from the nuclear medical image, and anatomical landmarks or, for 
instance, additional functional information from the other modality (6). 
 
2.3 Positron emission tomography (PET) 
 
A positron emission tomography scanner is in its simplest form a circular so-called “gamma 
camera” (a detector system sensitive to gamma radiation), like those used in scintigraphy, that 
reconstruct a 3D image in the same way a CT does. The main difference is that most CT have 
an x-ray tube to produce radiation to shine through the patient, and one image sensor in the 
opposite end; This does circular movements around the patient to make 2D slices of the patient. 
In a PET-scan the substance producing the radiation is inside the patient, and therefore it can 









When a radiopharmaceutical, as the ones used for PET (see below in 2.6 
Radiopharmaceuticals), produces two gamma photons travelling in opposite directions, two of 
the sensors in the sensor ring will detect a spike approximately at the same time (fig.1). Using 
the position of the two sensors, the computer can calculate a line where the photons must have 
come from. With several of these lines in multiple directions, you can make a 2D slice 
representation of the patient. By making several of these slices and joining them together, you 
get a 3D reconstruction of the patient (7). 
Another technique in use in some PET-scanners is to look at the time difference between the 
two photons, and then calculate where on the line between the sensors the two photons must 
have occurred. This technique is called ‘Time of Flight’ (7). 
PET-scanners provides good contrast in pictures, but poor anatomical resolution. Therefore, it 
is normal to have scanners with both a PET-detector ring and a CT-scanner or MRI-scanner in 
front. By using the exact position of the table on which the patient is lying, and the distance 
between the CT-scanner and the PET-scanner, one can overlap these two images, and get both 
a good contrast, and a good anatomical overview (7). 
 
Figure 1 A simplified figure showing an annihilation 
occurring in a patient inside a PET scanner, producing two 
gamma photons which travels to two sensors, which will 
detect a spike in approximately the same time. Note: 
number of sensors is not to scale. 
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2.4 Clinical use of PET-CT 
 
The role of PET as a diagnostic tool has been established in a wide variety of malignant and 
inflammatory diseases, both in initial staging and follow up (8). In clinic, the most common use 
of PET-CT is with the tracer 18F-fludeoxyglucose (FDG) (9). This is a glucose molecule 
marked with radioactive fluorine (18-F). This modified glucose molecule will enter glucose 
metabolism and become phosphorylated. The modified glucose molecule is prevented from 
being released from the cell, and therefore provides a good reflection of the distribution of 
primary glucose uptake. Cancerous and inflammatory cells have high glucose uptake, and thus, 
the use of FDG-PET/CT is useful in these clinical cases (5). FDG-PET/CT is used for accurately 
diagnosing, initial staging, response assessment, and follow-up in several cancers. FDG-PET is 
generally superior to CT scans alone (8). A meta-analysis found a sensitivity and specificity of 
96,8% and 77,8% respectively with monomodal FDG-PET in diagnosing lung tumours, 
compared to 61% and 79% with CT alone (10). Inflammatory diseases where FDG-PET(-CT) 
is often used, are large vessel vasculitis, sarcoidosis, and infection with unknown focus (5). 
With the development of new tracers, new ranges of applications emerge. This is useful in areas 
where FDG-PET has been of little value. The central nervous system (CNS) have a high 
baseline glucose metabolism, and with regular FDG-PET, the signal-to-baseline ratio is not 
sufficient to give good contrast between regular, neurological tissue and pathological processes 
in the same area (11). To overcome this, more specific tracers have been used for neurological 
diseases, like amyloid-β tracers in Alzheimer’s disease  (12). 
Prostate cancer is also a diagnosis that is difficult to determine the extent of its invasion and 
metastasis with FDG-PET because of the urinary excretion of FDG. This produce more 
background noise in the pelvic area, and cause a bad signal-to-noise ratio (13). The European 
guidelines from European Association of Nuclear Medicine (EANM) recommends the use of a 
prostate-specific membrane antigen (PSMA) tagged with generator produced 68-Gallium (68-
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2.5 Radioactive decay 
 
Radioactive decay is when the nucleus of an unstable isotope decays to a lower energy state. 
When an unstable nucleus decays, a small portion of the mass will transform into energy, as 
described in Einstein’s mass-energy relationship.  
E= mc2 
E is energy, m is mass and c is the speed of light in vacuum. This energy is released as radiation 
in some form. Radiation can be divided into two main categories, electromagnetic radiation and 
particle radiation. Electromagnetic radiation is a form of energy that does not have mass or 
charge. This package of energy is called photon or light quanta. This radiation can behave both 
as waves and as particles, and have the velocity of light. Examples of electromagnetic radiation 
are gamma-rays, x-rays and visible light. Particle radiation is particles with mass, that can have 
charge, and that they are emitted when the nucleus decay. Their velocity is determined by the 
kinetic energy they receive in the decay (7). 
There are several pathways by which a nucleus can decay, but this thesis will focus on the 
positron decay, since it is most relevant to the PET. 
Positron decay occurs when a nuclide has a higher proton/neutron-ratio than the nearest stable 
nuclide. Another requirement is that the parent nuclide must have 1,022 MeV more mass-
energy than the daughter nuclide. This is to satisfy the energy conservation law. In a positron 
decay a proton is converted to one neutron (n), one positron (β+) and one neutrino (v) (7). The 
positron and the neutrino are ejected from the decaying nucleus in the process, sharing the 
kinetic energy between them, whereas the neutron is confined to the new nucleus. 
P  n + β+ + v  
A positron is the antiparticle of the electron, with a charge of +1, instead of the electrons -1 
charge. In the presence of matter, the lifespan of a positron is extremely short. When travelling 
through a medium, the positron will only travel a short range before it loses its kinetic energy 
and meets an electron. When this happen, they will interact in a process called annihilation 
giving rise to two gamma photons which are emitted in opposite direction. These are the 
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gamma-rays we can detect in a PET-scan. Some examples of nuclides which mainly decay by 




A Radiopharmaceutical is a biologically active molecule that is coupled with a radioactive 
isotope. The biological molecule depends on the biological component or pathway one wants 
to study, such as an antibody, metabolic pathway or an amino acid. In theory, this can be every 
molecule in the body, but is limited to what type of isotope that can chemically bond with the 
chemical compound that is of an interest (4). 
To make radiopharmaceuticals you first must make or extract the radioactive isotope. To do 
this you need a particle accelerator or a generator. The most common particle accelerator in use 
is the cyclotron. The principle of this is that it accelerates particles, for instance protons, in a 
spiral to make a particle beam. This beam hits a target with such force that it creates a nuclear 
reaction. By bombarding different targets, one can make different isotopes, also radioactive 
ones (4). 
The second step is to chemically bind this isotope to the biologically active molecule that is of 
interest, for instance glucose or an amino acid. Some isotopes have such a short half-life that 
they must be channelled directly from the cyclotron, to the patient (7). 
Because of its relatively long half-life of 110 minutes and its chemical avidity, F-18 is the most 
common isotope in use. It can bind to glucose to make FDG which is suitable to monitor glucose 
metabolism, for instance in cancer and inflammatory diseases (7). F-18 FDG has proven itself 
to have a high clinical value in a variety of clinical cases due to being able to target many 
different diseases. 
Other isotopes in clinical use are nitrogen-13 and rubidium-82 in cardiac perfusion imaging 
(15), and nitrogen-13, carbon-11 (16), and copper-64 in neuroimaging (11). These isotopes are 
not in use in UNN, so their physical and pharmaceutical properties will not be further discussed 
in this thesis.   
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2.7 Pearson’s Chi Square test 
 
In this study, the subgroups within the patient data will be compared to each other using the 
Pearson’s Chi Square test. Pearson’s Chi Square test is a statistical test to evaluate if there is 
statistically significant difference between a group and an expected, theoretical distribution in 
a population. A null hypothesis is formulated, normally that there is no difference between the 
groups. Pearson’s Chi Square test can be used to test whether the null hypothesis is correct or 





O is the observed number and E is the expected number. After finding the X2 the degrees of 
freedom (dF) in the population needs to be determined. This means finding out how many 
variables are needed before the rest can be calculated. This is expressed by the equation below 
where N is the total number of observations. 
𝑑𝐹 = 𝑁 − 1 
When both X2 and dF is found, standardized tables are used to determine the P-value of the test. 
The P-value determine if the difference between the group and the theoretical distribution in 
the general population is statistically significant to the required degree.  
The Pearson’s Chi Square test has some predetermined assumptions. The first assumption is 
that the data of interest is a true random sampling from a fixed distribution in a population. The 
second assumption is that the sample is of sufficient size to truly reveal the difference. If not, a 
false negative error can occur. The third assumption is that all cells in the table has sufficiently 
large numbers. A rule of thumb is that it is necessary to have 5 or more in all cells in a 2x2 
table, and 5 or more in 80% of the cells in a larger table. If this is not met, the Yate’s correlation 
can be used. The last assumption is that the observations are independent of each other (17).  
 
 




The idea of launching PET service in Norway was first discussed in 2000 (3). The decision to 
create a PET centre in Norway was taken in 2004 (18), and the first PET centre was built in 
Oslo in 2005. In 2009, the Norwegian Knowledge Centre (Kunnskapssenteret) calculated that 
the number of PET/CT scanners needed in Norway was between 4 and 14, depending on 
whether PET/CT should be implemented in radiotherapy planning or not (19). 
Following this introduction of PET/CT service in Norway, it became clear that there was an 
uneven distribution of availability that was dropping with the distance from the centre, 
especially in Northern Norway (20). To counteract this trend, the University Hospital in 
Northern Norway initiated a process to establish a PET/CT scanner in Tromsø.  
The PET/CT scanner in Tromsø was established in May 2010. The scanner was supposed to 
serve Northern Norway, and its three counties, Nordland, Troms and Finnmark. The city of 
Tromsø is located approximately in the centre of this region with 900 km to the Russian border 
in the east, and 800 km to the southern border of Nordland.  Due to this vast area, and a 
population of only 464 000 inhabitants (2010), establishing a PET/CT scanner here would 
demand a cost-effective solution.  
At first, FDG was obtained through MAP Medical Technologies in Helsinki, Finland. Initially 
a private company served Tromsø, along other hospitals in Scandinavia and Estonia, with a 
mobile PET/CT scanner placed in a semi-trailer. This solution was replaced in October 2011 
by a stationary scanner in Tromsø, and in November 2012 a permanent, self-owned PET/CT 
scanner was established (20). Since 2015 the FDG has been produced in Oslo due to a new 
tender process.  
In 2015, a study that looked at the availability to PET/CT in the different counties, Nordland, 
Troms and Finnmark was published (20). This study observed that the availability decreased 
with longer travel distance to the PET/CT-scanner. The difference was most prominent for the 
southern county in Northern Norway, Nordland. This study reveals a need to make PET/CT 
examination more available (20).  
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After this study, the section of nuclear medicine (now Department of PET Imaging Centre), 
UNN, did take some measures to ensure that patient from Nordland got equal access to PET/CT 
as the rest of the region. The measures taken were. 
- 2015: The multidisciplinary team at Nordland Hospital, Bodø got one slot reserved each 
week (20). 
- Increased capacity of the scanner: In 2016, the number of days with scanning per month 
increased from 4 to 5, and in 2017 it increased to 8 days a month (personal 
communication dr. Rune Sundset, UNN). Since these measures was taken in 2016 and 
2017, they have not affected the data set in this study. 
2.9 Aim of Study 
 
This is a follow-up study of Norum 2015 (20). The aim of this study is to investigate whether 
the difference in availability to PET/CT service between the three northernmost counties in 
Norway, which was observed between 2010 and 2013 continued in 2014 and 2015, or if there 
is an improvement in availability to the PET-service at UNN, Tromsø. 
This study does not look at the clinical outcome of the patient, and is not meant to verify the 
clinical value of FDG-PET/CT. This study does not evaluate the quality of the referral practice 
within the different hospitals and health trust in the region.  
 
3 Methode 
3.1 Data included and analysis tools 
The population in this study consists of all PET-CT scans at UNN in the period 2014-2015. The 
data was retrospectively extracted from the medical imaging information system (TRIS), and 
then manually checked against the written documents at the PET Imaging Centre. The data 
extracted was name, personal ID number, date of examination, residence and clinical problem. 
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To make the final dataset, Microsoft Excel 2016 was used, and IBM SPSS 24 was used for 
statistical analysis and descriptive analysis. By using the personal identification number, age 
and sex was obtained. By reading the clinical problem, all patients were categorised using the 
same standard diagnostic categories as the previous study (20). However, in the dataset received 
from 2010-2013 thyroid cancer had been categorized as “head and neck cancer”. To avoid 
disparities, this definition was also used in this study. 
With the registered residence, the population was divided into three categories based on their 
county, and the driving distance from residence to UNN, Tromsø was calculated using the 
postal code and Google Maps (www.maps.google.com).  The number of inhabitants in the three 
counties (Nordland, Troms and Finnmark) was calculated using data from Statistics Norway 
(www.ssb.no). 
The three patient groups were compared to each other with descriptive statistics. The rate of 
number of PET/CT examinations per capita was calculated, and then compared with a regional 
average to create a ratio number between PET scans in county and in the region. This number 
were compared with the same numbers from Norum 2015 (20) in the period 2010-2013. 
Pearson’s Chi Square test were used to verify a significant difference between Nordland, Troms 
and Finnmark in the period of 2014-2015. 
Due to the switch from TRIS information system to SECTRA information system, the home 
address from the last 183 patients in 2015 was not included in the statistics. Unfortunately, this 
error was not discovered in time to be corrected in this thesis, but will be included, together 
with the 2016 data in the planned publication. The implication of this in the current study is 
examined in the discussion. 
3.2 Authorisation  
 
The study was carried out as a quality of care analysis and consequently no ethical committee 
or Data Inspectorate approval was necessary. Similarly, no approval from the Regional 
Committees for Medical and Health Research Ethics (REK) or from the Norwegian Social 








The number of PET/CT scans performed per year at UNN Tromsø has increased since the start 
in 2010 (figure 3). The total number of PET/CT scans was 907 in the period 2014-2015 in 825 
individual patients. This gives an average of 1,1 examinations per patient. There is more than a 
fourfold increase in scans per year from 2010 to 2015. 
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Table 1  An overview of PET/CT examinations. Total, sex, county and diagnosis are shown in total (n) and 
percentage (%) (2014-2015). 
 
 
There was no significant difference between age distribution between genders. The mean age 
among males was 61, and 59 years among females. Standard deviation was 15,4 and 15,5 
respectively. As seen here, there is a discrepancy between the total number of PET/CT scans 
(907) and the combined number of PET/CT from the three counties (760) (table 1). This is 
  Examinations 
Variables  PET/CT % 
Total  907 100 
Sex  Male 551 61  
 Female 356 39 
County Nordland 348 46 
 Troms 268 30 
 Finnmark 145 16 
Diagnosis Lung cancer 330 36,4 
 Lymhpoma 163 18,0 
 Head and neck cancer 91 10,0 
 Malignant melanoma 61 6,7 
 Colorectal cancer 55 6,1 
 Gynaecological cancer 34 3,7 
 Urogenital cancer 30 3,3 
 Upper GI-cancer 22 2,4 
 Breast cancer 5 0,6 
 Cancer, unknown origin 26 2,9 
 Other cancers 30 3,3 
 Inflammatory disease 46 5,1 
 Sarcoidosis 4 0,4 
 Others 5 0,6 
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due to the change from TRIS image information system to SECTRA that led to a deletion of 
the home city number for the patient that had a PET/CT scan in November and December in 
2015, and affected 147 patients. To not distort the statistics, these 147 patients were left out in 
the statistics below where the counties are compared. 
Table 2 The ratio of PET/CT exams/population in total and in each county. The figure of all three northern 
counties was set to one in each diagnostic group. (For example: All exams: 760/479 000 inhabitants = 0,16% 
=1.00. The same numbers for the period 2010-2013 were gathered from Norum 2015 (20) for comparison. 
 Nordland Troms Finnmark 
2010-2013 2014-2015 2010-2013 2014-2015 2010-2013 2014-2015 
Lung cancer 0,57 0,89 1,34 0,96 1,66 1,4 
Lymphoma 0,67 0,89 1,62 1,11 0,74 1,1 
Malignant 
melanoma 
0,99 1,16 1,02 0,89 0,99 0,72 
All examns 0,71 0,91 1,32 1,04 1,26 1,2 
 
  
The general distribution of PET/CT use is more evenly distributed in the period of 2014-2015 
compared with the period of 2010-2013, but in some diagnostic groups, the discrepancy is 
higher than the average. The group with the greatest difference was the lung cancer group, 
where Finnmark had 57% more PET/CT scans than Nordland. As was also found in the 
previous analysis Nordland is lowest in all groups, except for malignant melanoma, where 
Nordland had a higher PET/CT use. The other diagnostic groups were not compared between 
the counties because of small numbers of patients (table 2). 
The mean traveling distance by car was 406 km (std.dev 271 km). The range was from 4,8 km 
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The incidence rate between Nordland, Troms and Finnmark in lung cancer (all types) and 
malignant melanoma. Finnmark has a considerable higher lung cancer incidence than both 
Nordland and Troms, and there is a gender difference also.  
In malignant melanoma Troms has a higher incidence rate than both Nordland and Finnmark, 
and Finnmark has lower incidence rate than Nordland.  
Table 3 Age standardized lung cancer incidence per 100 000 capita in Nordland, Troms and finnmark, as well as 
the national average (21) 
 Male Female Average 
Nordland 77,9 50,1 64 
Troms 81,3 49,8 65,55 
Finnmark 97,7 65,9 81,8 
Norway 75,8 52,8 64,3 
 
Table 4 Annual average 2011-2015. Age-standardized incidence rates per 100 000 inhabitants of melanoma of 
the skin in Nordland, Troms and Finnmark, as well as the national average (21). 
 Male Female Average 
Nordland 22,2 20,8 21,5 
Troms 28,3 23,3 25,8 
Finnmark 15,5 16,4 16 











In this study, it has been documented that the number of PET/CT scans per million inhabitants 
in Northern Norway has increased from 270 in 2010 to 1069 in 2015. In 2012 the European 
average was 1200 examinations per million inhabitants (9). Norway had a national average of 
1500 PET scans per million inhabitants in 2014  (9). Thus, Northern Norway is below both 
European and Norwegian average. In comparison, Denmark had an average of 4900 
examinations per million inhabitants in 2011 (9). The number of PET scans per million to cover 
all indications, was calculated to be 2026,5 scans/million by Bedford and Maisey in 2004 (22). 
Based on the rapid increase in number of PET/CT scans, and the fact that UNN has doubled 
their capacity from 2015 to 2017, it is reasonable to hope that the PET incidence in Northern 
Norway will reach European and Norwegian standards within few years. To control this, a new 
follow up study with 2016 and 2017 data needs to be conducted. 
The significant increase in number of PET/CT scans in Northern Norway can be seen all over 
Norway (9). The total number of PET scans in Norway has increased from 80 in 2005 to 7525 
in 2014 (9). In the western part of Norway, Haukeland University Hospital opened its PET 
service in 2009 and have had an increase from 293 in 2009 to 1616 in 2014 (9). This indicates 
that when a service is opened, a period of even increase is seen the first years. At the same time, 
the widespread use of PET/CT has increased in Norway. It is natural that when a service is 
opened, the demand will increase when the service is implemented in more guidelines in the 
future.  
In Norum’s study (20) Nordland (0,10%) had half the number of PET/CT scans per head of 
population when compared to Troms (0,20%) and Finnmark (0,19%). When compared to the 
regional average, the values were 0,71, 1,32 and 1,26 respectively (table 2). In this dataset, the 
same values were 0,91, 1,04 and 1,21 (table 2), which has far less variation between the 
counties. This shows a significant reduction in disparity between counties, but still, there is a 
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One reason for this disparity could be due to a “leakage” of patient from Nordland to other 
PET-centres in Norway. A frequently used centre is the private PET/CT scanner at Aleris in 
Oslo. Upon request, they reported that there were 78 PET/CT scans referred from a hospital 
within Northern Norway in 2015. This is 13% of all PET/CT examinations in northern Norway. 
Aleris also stated that ⅔ of the examinations was performed during the second half of 2015. 
This means that they have had an increase during 2015, and therefore one cannot assume that 
there has been an even percentage over time of patient from Northern Norway, and that this 
number has been lower in 2014 and first half of 2015.  Since all these are within the same health 
trust, the data received from Aleris did not distinguish between the different hospitals or 
counties. Assuming a 13% percent referral rate, this could potentially shift the observed 
distribution between counties. Another explanation of this “leakage” is that the patient groups 
which is referred to other PET centres is referred because of clinical cases which UNN, Tromsø 
do not have PET/CT protocols for. This explanation would mean a more evenly distribution 
between counties than if one specific hospital referred more patient to other PET centres. To 
investigate this, a better method for controlling external use of PET/CT would have to be 
implemented.  
Lung cancer was the most common indication among the PET/CT patients, accounting for 36,4 
% of all patients (table 1). This means that differences in the lung cancer group can affect the 
general distribution in the PET/CT population to a high degree Finnmark has a 22% higher 
incidence of lung cancer than Nordland (table 3) (21), but had 36,5% more PET/CT scans in 
the lung cancer group. This implies that a difference in lung cancer incidence cannot explain 
all the difference in PET/CT use. The same was observed between Troms and Finnmark. 
Overall, Finnmark had a higher use of PET/CT per lung cancer incidence than both Troms and 
Finnmark, suggesting that there are other factors which affects the access to PET/CT 
examination in lung cancer patients. When all lung cancer patients were excluded, the 
difference between Troms and Finnmark evened out, while Nordland is still 18% below both 
Troms and Finnmark. A plausible reason for an increased lung cancer incidence in Finnmark is 
the historical smoking habits. Finnmark is still the county with the highest prevalence of daily 
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The role of PET/CT in malignant melanoma has been discussed (24). In stage I and II cancer, 
PET/CT has a high false positive rate, and the current consensus is that PET/CT adds little 
additional information in these patients (24). However, PET/CT is widely used in stage III and 
IV cancer. A retrospective study found that PET/CT had a sensitivity of 98,7% in patient with 
malignant melanoma, and recommended use in N and M staging (25).  PET/CT is considered 
the gold standard in evaluation of additional, unsuspected lesion in patients with known 
malignant melanoma stage IV. In this study, malignant melanoma was the only cancer subgroup 
where Nordland had a higher use of PET/CT than Troms and Finnmark. Nordland was 30% 
above Troms and 61% above Finnmark in use of PET/CT. In Norum’s study (20), it was found 
that malignant melanoma had an even distribution, in contrast with the other subgroups, where 
there was a big discrepancy. The strong cooperation between the plastic surgery department in 
the hospitals in Bodø and Tromsø was suggested to be one of the reasons for this. However, 
this does not explain a discrepancy of 60% between Finnmark and Nordland. Finnmark has 
some lower melanoma incidence rates (table 4), but Troms has the highest incidence in both 
genders, and should therefore be expected to have a higher PET/CT incidence in this patient 
group. Also, the difference in cancer incidence between Nordland and Finnmark is only 30%, 
and therefore potentially only accounts for half of the difference. Another factor that could 
contribute to this is the number surgeons from Tromsø that work in Bodø, or other reference 
differences between the hospital. This should however not be expected since the same surgeons 
work in both places.  
One of the strength of this study, was the high number of patients included. All patient that had 
a PET/CT scan during the period was included, and therefore minimizing the risk of selection 
bias and promoting generalisation. One of the weaknesses with this study was that a portion of 
the patients in the population did not get registered with their home address. However, since 
this error happened in a point in time for all hospitals, the risk of bias is much smaller than if 
the error happened with a single hospital, or a single patient group, and the only implication is 
that there was a smaller patient number than originally planned. This error was not discovered 
in time to improve before the due date for this thesis, since it would have to been corrected 
manually in the patient data program (DIPS). 
The future of PET examination in Northern Norway is looking bright. The PET imaging centre 
in UNN, Tromsø is nearing completion. Here, an inhouse cyclotron will make new 
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radiopharmaceuticals available and widen the research potential. A new PET/CT and a new 
PET/MR will further increase the capacity of the PET imaging centre. This, alongside a 
PET/CT stationed in Nordland Hospital, Bodø will further increase capacity and make PET/CT 
more available for the population within Nordland.  
6 Conclusion  
 
The disparity in availability to PET/CT service in Northern Norway has decreased since 2010-
2013, but there is still a difference between the three counties. This was true for all diagnostic 
groups, except for malignant melanoma, where the disparity had increased. Overall, Finnmark 
has a higher use of PET/CT than both Nordland and Troms, and difference in cancer incidence 
cannot explain all the difference. This suggest that other factors affect the access to PET/CT 
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levermetastaser for å 
avgjøre om de er 
operable. Første 
randomiserte studie om 
temaet 
Randomisert kontrollert studie 
 
Studiet ble designet som en multisenter, randomisert kontrollert studie. Studiet ble designet for å 
oppdage en 15% reduksjon, og man trengte derfor 75 pasienter i hver gruppe.  
Kontrollgruppen ble satt opp til operasjon uten videre diagnostikk etter inklusjonskriteriene ble 
bekreftet, mens casegruppen ble satt opp til 18F-FDG-PET innen to uker (1-5). 
Endepunkt ble definert som «resultatløs lapratomi» hvis «resultatløst» ble definert som kirurgi som ikke 
resulterte i komplett remisjon i oppfølgingsperioden på 3 år. To andre endepunkter var overlevelse og 
sykdomsfri overlevelse. 
Inklusjonskriterier var pasienter med tidligere colorektal cancer som ble operert med fri 
reseksjonsrand, som hadde fått påvist levermetastaser (og maks to lungemetastaser) med konvensjonell 
CT-diagnostikk.  
Eksklusjonskriterier var følgende: Tidligere andre maligniteter som ikke hadde vært sykdomsfri i minst 
10 år (unntatt in-situ carcinoma i cervix og nonmelanoma hudkreft), tegn til leversvikt, aktiv infeksjon 
og dårlig regulert diabetes mellitus. 
Gruppene ble sammenlignet med Fisher exact og T-test for kvantitative målinger. Overlevelse og 
sykdomsfri overlevese ble målt med Kaplan-Meier.  
Fem pasienter i casegruppen fikk kansellert operasjonen 
sin. Tre pga ekstrahepatisk metastaser og to pga 
(korrekt) analyse som benign sykdom. Det betyr at 70 
personer i casegruppen ble operert. Totalt fikk 45% av 
kontrollgruppen tilbakefall, mens kun 28% fikk det i 
casegruppen. Det gir en relativ risikoreduskjon på 38%, 
som gir NNT på 6 PET-skanninger for å spare en 
unødvendig lapratomi.  
Det var ikke signifikant forskjell i verken overlevelse 
eller sykdomsfri overlevelse (P=0,378 og P= 0,194) 
18F-FDG-PET forutså negativt utfall av lapratomi i 15 
pasienter, men funnene ble ignorert i 10 av disse av 
teamet som avgjorde operabilitet. Alle disse 10 fikk 
tilbakefall av sykdom.  
En av styrkene til denne studier var det 
randomiserte designet. Det har kun blitt 
gjort nonrandomiserte studier tidligere på 
dette feltet. Multisenterdesignet øker også 
generalisering og minsker sjansen for bias.  
Svakhetene med studiet er at spørsmålet om 
operabilitet ble gjort fra case til case og at det 
i 10 tilfeller viste seg at PET-funnene ble 
ignorer. Dette fører til en maskering av det 
virkelige potensialet til PET-undersøkelsen, 
og differansen mellom observert forskjell og 
faktisk forskjell blir i større grad opp til 
retrospektive analyser. En annen av 
svakthetene til studien er at ved 
publikasjonsdato var allerede mange av 
retningslinjene for operabilitet endret, man 
hadde fått perioperativ, adjuvant 
kjemoterapi inn i retningslinjene, og 
multimodale PET-skannere hadde allerede 
gjort innpass i klinikken.  Dette er med på å 
gjøre studien mindre aktuell klinisk, men 
ikke i slik grad at den ikke er relevant.  
Funnene stemmer overens med to 
metaanalyser som ble gjort av alle 
nonrandomiserte studiene som var gjort på 
tidspunktet 
Konklusjon 
 18-F-FDG-PET kan 
redusere antall 
resultatløse reseksjoner 
med 38%, og har 
potensiale for ennå 
større reduksjon hvis 
funnene blir tatt mer 
hensyn til, og når man 
nå har fått multimodale 
PET-skannere 
(PET/CT og PET/MR) 
Land 
Nederland 
År data innsamling 
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Tverrsnittsstudie (diagnostisk testvurdering) 
14 pasienter med histopatologisk bekreftet NET mellom nov. 2009 og jan 2010 som ble henvist til 
konvensjonell somatostatin receptor imaging (SRI). Ingen randomisering eller kontrollgruppe 
Inklusjons-/eksklusjonskrit. 
- Histopat. Bekreftet NET 
- Henvist SRI 
Datagrunnalget 
- 14 pasienter med NET 
- Scan etter 1 time (n=14), 3 timer (n=12) og 24 timer (n=5)  
Utfall (outcome) validering 
(for eks. diagnose) 
- Antall Volumes of interest (VOI) 
- Bildekvalitet 
- PET/CT- og SPECT/CT-bildene ble analysert av to team med to erfarne nukleærmedisinere, som 
ble blindet for hverandres konklusjoner.  
- Som kontrollgruppe ble kun CT-bildene avlest av en erfaren radiolog 
- For å validere resultatene ble det gjort kontroll ved 18 mnd ved CT og konvensjonell SRI 
Statistiske metoder 
Gjennomsnitlig doseberegninger i de forskjellige organene ble gjort ved gjennomsnitt av 5 pasienter med 
standardavvik. 
Antall lesjoner ble summert for hver modalitet.  
Hovedfunn:  
- 64Cu-DOTATATE PET/CT viste seg å finne flere 
vervifiserte lesjonen enn 111In-DTPA-octreotide 
SPECT/CT. Henholdsvis 219 lesjoner mot 115 lesjoner. Alle 
lesjonene som ble funnet på SPECT/CT ble også funnet på 
PET/CT. I 5 pasienter ble det funnet lesjoner i organer som 
ikke var positive på SPECT, noe som er ekstra interessant da 
det forandre behandlingsgrunnlaget. 
Bifunn: 
- PET/CT ga betydelig bedre bildekvalitet og 
oppløsning enn SPECT/CT.  
- I bakgrunn av de 5 pasientene som ble målt 
doseberegning på, fant man ut at 111In-DTPA-
octreotide SPECT/CT ga betydelig høyere 
dosebelastning enn 64Cu-DOTATATE  PET/CT. 
Henholdsvis 12 mSv og 6 mSv 
- Bildene kan tas 1 time etter injeksjon, og pga middels 
lang halveringstid (12,701 min) kan 64Cu-
DOTATATE produseres sentralt og distribueres til 
andre fasiliteter i området.  
Det er betydelig bedre bilder ved bruk av 
64Cu-DOTATATE PET/CT enn 111In-
DTPA-octreotide. Det har også blitt påvist at 
det blir oppdaget flere lesjoner ved PET/CT 
enn SPECT/CT i de samme pasientene.  
PET/CT gir lavere stråledose. Forfatterne 
mener at til tross for det lave antallet pasienter 
det ble gjort stråledoseanalyse på, er 
forskjellen så stor at det er et sterkt resultat. 
Resultatet styrkes av at det ble gjort på de 
samme pasientene for både PET og SPECT.   
Man har sett samme resultat for andre 64-Cu-
merkede somatostatinanaloger hvor det er 
sammenlignet med 111In-DTPA-octreotide 
SPECT/CT.  
Forfatterne diskuterer om forbedringen er 
grunnet isoopen(64Cu) eller analogen 
(DOTATATE). Man har sett at 68Ga-
DOTATATE og 68Ga-DOTATOC også gjør 
det bedre enn 111In-DTPA-octreotide, slik at 
man må sammenligne 64Cu og 68Ga direkte 
for å avgjøre dette.  
Konklusjon 
 64Cu-DOTATATE 
egner seg godt til 
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Gruppe 1: personer med Cardiovascular implantable electronic devices (CIED) med mistanke om infeksjon 
Gruppe 2: Personer med CIED uten mistanke om infeksjon, men som ble henvist til PET-CT for onkologiske grunner.  
Inklusjons-/eksklusjonskrit. 
Fått implantert CIED mellom 2009 og 2011. Hatt den implantert i minimum 2 mnd.  
Datagrunnalget 
40 i casegruppe, 40 i kontrollgruppe 
Utfall (outcome) validering 
(for eks. diagnose) 
Bildene ble undersøkt av to nukleærmedisinere som var blindet for andre kliniske opplysninger. Hvis de var uenige, 
møtes de for å enes om en konsensus 
Gullstandard ble i denne testen satt som positiv dyrkning ved eksplantasjon, eller klinisk oppfølging i 1 år mtp infeksjon 
Statistiske metoder 
Det ble beregnet sensistivitet, spesifisitet, NPV og PPV 
  
Hovedfunn: 
Sensitivitet 83%, spesifisitet 
95%, NPV 88% og PPV 
94%. Alle i kontrollgruppen 
var negativ.  
Styrke: Sterke resultater, spesielt høy spesisfisitet.  
Svakhet: Retrospektiv studie, samt vanskeligheter med å 
detektere forhøyet FDG-opptak grunnet høy bakgrunnsopptak i 
myokard. Dette skyltes manglende  dietregulering forut for 
undersøkelsen 
Hva diskutere forfatterne ? 
Forfatterne diskuterer om FDG-PET/CT skal implementeres i 
utredningsalgoritmen. Spesielt pga den høye spesifisiteten mener 
de at det burde implementeres. 
Annen litteratur som styrker funnene? 
PET/CT brukes mer og mer på forskjellige typer infeksjoner, og 
tar i større grad over for leukocyttscintigrafi. Det er andre studier 
som har undersøkt mtp endokarditt. 
Chen, W., Kim, J., Molchanova-Cook, O.P. et al. Curr Cardiol 
Rep (2014) 16: 459. doi:10.1007/s11886-013-0459-y 
Og en studie har sett på om man skal gjøre undersøkelsen 1 time 
eller 3 timer etter injeksjon av F18-FDG 
Leccisotti, L., Perna, F., Lago, M. et al. J. Nucl. Cardiol. (2014) 
21: 622. doi:10.1007/s12350-014-9896-2 
Konklusjon 
 18-F-FDG-
PET/CT er nyttig 
i diagnostikken av 
infeksjon i CIED. 
De lovende 
resultatene i 
denne studien må 
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Formålet med studien er 
å validere bruk av 
PET/MR ved NSCLC, 
og sammenligne med 
PET/CT for å 
vervifisere evt. fordeler 
med noen av 
modalitetene. Målet var 
nøyaktig TNM-staging 
Tverrsnittstudie 
52 pasienter med mistenkt eller biopsivervifisert NSCLC ble rekrutterting til studien. 
Alle pasientene ble undersøkt etter retningslinjer med EBUS, kontrast-CT og til slutt 
trimodal PET/CT + MR. 
10 pasienter ble ekskludert etter at biopsi viste noe annet enn NSCLC. 
Datagrunnalget 
42 pasienter, 29 menn, 13 kvinner. Median alder 69 år (35-89) 
Bildene ble delt ut til to grupper med to nukleærmedisinere i hver gruppe. Begge 
gruppene analyserte monomodale PET-bilder, så analyserte gruppe A PET/CT-bildene, 
mens gruppe B analyserte PET/MR-bildene. Operatørene ble blindet for klinikk, bortsett 
fra mistanke om NSCLC. 
Utfall (outcome) validering 
(for eks. diagnose) 
Histologi utgjorde gullstandard for T og N-staging, mens andre bildemodaliteter ble 
brukt for M-staging, enten kontrast-CT eller kontrast-MR 
Statistiske metoder 
Forskjeller mellom TNM-klasifiseringen ut fra PET-bildene ble analysert med K-
statistikk, mens forskjellene i TNM-klassifiseringen fra PET/CT og PET/MR-bildene ble 
analysert med Wilcoxon signed-ranked test. 
  
Hovedfunn: 
Sammenlignet med PET/CT, ga PET/MR 
ekstra informasjon i 7 tilfeller i 5 pasienter 
(9%). Sammenlignet med PET/MR ga PET/CT 




Publiserer negativ data.  
Svakhet 
Studie delvis finansiert av GE-Healthcare, dog ingen ansatte i GE jobbet 
med studien elle behandling av data.  
Ikke alle primærtumorere ble resektert av etiske årsaker, men man har 
gjennom biopsi fått histologisk proøvemateriale fra alle tumorene. 
Hva diskutere forfatterne ? 
Muligheten for å bruke andre MR-protokoller i framtidige forsøk, men 
de tar så lang tid at det kan gå utover kvaliteten på PET-bilden.  
Denne studien brukte ikke kontrastagenser, så den må tolkes med 
forsiktighet når den sammenlignes med andre studier som bruker 
kontrast.  
Konklusjon 
 Begge modalitetene har 
lignende diagnostisk 
nøyaktighet, med en 
positiv trend for 
PET/CT. Med mulig 
unntak av hjerne- og 
levermetastaser vil 
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Evaluere 18F-FDG-PET som 
førstelinjediagnostikk ved residiverende 
lanrynxcancer i stedet for invasiv laryngoskopi 
med biopsi som er standard i dag.  
Prospektiv randomisert studie. Ikke blindet. 
Deltakere ble rekruttert hvis de hadde mistenkt residiv minst 2 mnd etter (kjemo-)radioterapi. Mistanke med 
grunnlag av funn ved enten fleksibelt laryngoskopi eller ved symptomer. 
Eksklusjonskriterier var under 18 år, bevist residiv eller graviditet. 
Datagrunnlaget 
150 pasienter til sammen i alder. Randomisert i to grupper av dataprogram mtp å få to like store grupper i 
Utfall (outcome) validering 
Forskjell i antall unødvendige direkte laryngoskopier. Pasienter i PET-gruppen ble kun sendt til laryngoskopi 
hvis PET var positiv. Unødvendig laryngoskopi var definert som at det ikke ble oppdaget cancer i hverken 
første laryngoskopi eller i oppfølgingsperioden på 6 og 12 mnd 
Statistiske metoder 
Statistikken ble utført av en klinisk statistikker. Fisher’s exact test ble brukt for å kalkulere hvor mange 
pasienter som trengtes i hver gruppe for å se en signifikant forskjell. Logistisk regresjon ble brukt for å se 
etter konfunderende forskjeller i røyking, alder og klinisk stadie i cancer før radiotesrapi. De to gruppene ble 
sammenlignet med Chi-kvadrat eller fisher’s exact der hvor det var mer passende. T-test eller Wilcoxon ble 
brukt for å sammenligne kontinuerlige variabler. 
Hovedfunn: 
En algoritme som inneholder 
PET(-CT) kan effektivt 
redusere antall unødvendige 
invasive prosedyrer med 50% 
uten å gå på bekostning av 
pasientsikkerhet og mulighet 
for å overse kreft. Det ble gjort 
et falsk negativt funn på PET, 
men dette ble oppdaget i CT-
modaliteten i den bimodale 
skanneren. Dette er høyst 
uvanlig, da PET har høyere 
sensitivitet enn CT.  
Det var ingen forskjell i de 
pasientene som ble skannet 
med en PET- eller en PET/CT-
skanner. Dette kan være pga 
det relativt lave antallet 
pasienter 
Styrke: 
Den største styrken med denne studien er 
at den er randomisert og sammenligner to 
pasientgrupper i stedet for å ha en gruppe 
hvor man gjør begge undersøkelsene. 
Det er en multisenterstudie og man øker 
antallet pasienter og generaliserer 
prosedyrene i større grad, og derfor 
minsker sjansen for bias.  
Svakhet 
Studien var ikke blindet for hverken 
pasienter, leger eller annet personell som 
var med i studien. Det kan være vanskelig 
å se hvordan en slik studie skulle vært 
blindet. Da dette også ikke er basert på 
subjektive mål, mener jeg at mangelen på 
blinding ikke påvirker studien i negativ 
grad 
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 Ved bruk av 18F-FDG-PET kan man redusere 
behovet for direkte laryngoskopi med 50% uten å 
senke kvaliteten på diagnostikken, eller øke 
dødligheten 
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